Beclomethasone: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 29, 2026🚩 Report this page

Beclomethasone

Active ingredient · 4 therapeutic classes

Sold as Trimbow · Trydonis · BECONASE ALLERGY/HAYFEVER · QVAR 100 AEROSOL · QVAR 100 AUTOHALER

GB MHRAEU EMACA Health Canada

Drug class: Corticosteroids Acting Locally
Availability: See label
Routes: Nasal
Markets covered: 3
Products on record: 112

A07EACorticosteroids Acting Locally R03BAGlucocorticoids D07ACCorticosteroids, Potent (Group Iii)R01ADCorticosteroids

Overview

Beclomethasone is an active pharmaceutical ingredient in the Corticosteroids Acting Locally group (A07EA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	109	May 29, 2026
EU European Union	EMA	2	March 17, 2026
CA Canada	Health Canada	1	March 22, 2025

GBUnited Kingdom· MHRA

109 products

Uses

GBOfficial regulatory label· revised October 31, 2025[1]

Respocort is indicated in children aged 5 and over, adolescents and adults for the prophylactic management of mild, moderate or severe asthma.

How to take

EUEuropean Union· EMA

2 products

Uses

EUOfficial regulatory label· revised March 17, 2026[2]

1).

How to take

EUOfficial regulatory label· revised March 17, 2026

CACanada· Health Canada

1 product

1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].

Sources & citations

[1]MHRA (UK) · PL528110006 · revised October 31, 2025
[2]European Medicines Agency · EMEA/H/C/004702 · revised March 17, 2026
[3]Health Canada (DPD) · 02238577 · revised March 22, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

NOTE:
The recommended total daily dose of Respocort is lower than that for current beclometasone dipropionate containing products and should be adjusted to the needs of the individual patient.
ADULTS ANND ADOLESCENTS OVER 12 YEARS STARTING AND MAINTENANCE DOSE:
It is important to gain control of asthma symptoms and optimise pulmonary function as soon as possible. When patients’ symptoms remain under satisfactory control, the dose should be titrated to the lowest dose at which effective control of asthma is maintained.
To be effective inhaled Respocort must be used on a regular basis even when patients are asymptomatic.
Therapy in new patients should be initiated at the following dosages:
Mild asthma: 100 to 200 micrograms per day in two divided doses Moderate asthma: 200 to 400 micrograms per day in two divided doses Severe asthma: 400 to 800 micrograms per day in two divided doses Patients on budesonide inhalers may be transferred to Respocort as described below: The general approach to switching patients to Respocort involves two steps as detailed below.
Specific guidance on switching well-controlled and poorly controlled (symptomatic) patients is given below the table.
Step 1:
Consider the dose of budesonide-containing inhalers appropriate to the patient’s current condition.
Step 2:
Convert the budesonide dose to the Respocort dose according to the table below. Daily Dose of Beclometasone Dipropionate (micrograms) Budesonide Inhaler 200- 250 300 400- 500 600- 750 800- 1000 1100 1200- 1500 1600- 2000 Respocort 100 150 200 300 400 500 600 800 Patients with well-controlled asthma using budesonide inhaler products should be switched to Respocort at a dose in accordance with the table above.
For example:
Patients on 2 puffs twice daily of budesonide 200 micrograms would change to 2 puffs twice daily of Respocort 100 micrograms. Patients with poorly-controlled asthma may be switched from budesonide inhaler products to Respocort at the same microgram for microgram dose up to 800 micrograms daily.
Alternatively the patient’s current budesonide inhalee dose can be doubled and this dose can be converted to the Respocort dose according to the table above. Patients on fluticasone inhalers may be transferred to the same total daily dose of Respocort up to 800 micrograms daily.
Once transferred to Respocort the dose should be adjusted to meet the needs of the individual patient. The maximum recommended dose is 800 micrograms per day in divided doses.
CHILDREN AGED 5 YEARS AND OVER STARTING AND MAINTENANCE DOSE:
Therapy in new patients should be initiated at the following dosages: Mild asthma: 100 micrograms per day in two divided doses Moderate asthma: 100 to 200 micrograms per day in two divided doses Severe asthma: 200 micrograms per day in two divided doses The minimum recommended dose is 50 micrograms twice daily and the maximum recommended dose is 100 micrograms twice daily, representing a total daily dose of 100 and 200 micrograms, respectively.
Children with well-controlled asthma on doses of up to 400 micrograms per day of beclometasone dipropionate administered from other currently available beclometasone dipropionate inhalers or equivalent may be titrated to a dose of 100-200 micrograms (in two divided doses) per day of Respocort.
During periods of deterioration in asthma control, the dose of beclometasone dipropionate may be increased to 200 micrograms per day in two divided doses. The dose should then be reduced to the minimum needed to maintain effective control of asthma.
Patients on fluticasone or budesonide inhalers may be switched to Respocort using the approach described earlier for adults and adolescents. Once transferred to Respocort the dose should be adjusted to meet the needs of the individual patient.
Special patient groups No special dosage recommendations are made for elderly or patients with hepatic or renal impairment. Method of administration Respocort is for inhalation use. Patients and carers should be instructed in the proper use of the inhaler, including rinsing out the mouth with water after use.
Patients should be advised that Respocort may have a different taste and feel compared to other inhalers. Respocort Autohaler is a breath-actuated inhaler which automatically releases the metered dose of medication during a patient’s inhalation through the mouthpiece and overcomes the need for patients to have good manual co- ordination.
The parent/guardian/carer as well as the patient should read the instruction leaflet before use. Before first use of the inhaler, or if the inhaler has not been used for two weeks or more, prime the inhaler by releasing two puffs into the air.
Respocort delivers a consistent dose, at temperatures as low as -10°C, without the need for the patient to wait between individual actuations. Instructions for use There is no need to shake the inhaler before use, as it is a solution.
Instruct the patient, parent or guardian/carer to remove the mouthpiece cover and check that the inhaler is clean and free from foreign objects. The Autohaler device should be held upright. The lever should be pushed to the upward position.
As this is an automatic device, the dose will automatically be released when the patient begins breathing with the inhaler. The patient should be advised to breathe out as far as is comfortable before placing the inhaler into their mouth.
They should then close their lips tightly around the mouthpiece and breathe in steadily and deeply through the mouth. After starting to breathe in, the patient should not stop breathing when there is a slight click and when they feel the actuation in their mouth as it is important to carry on breathing after the puff is released.
Whilst the patient is still breathing in, the inhaler should be removed from their mouth and they should hold their breath for 10 seconds and then breathe out slowly. The patient should not breathe out into the inhaler. After receiving the puff, the lever must be lowered […]

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised October 31, 2025[1]

A serious hypersensitivity reactions including oedema of the eyes, face, lips and throat (angioedema) has been reported rarely. As with other inhalation therapy, paradoxical bronchospasm may occur after dosing. Immediate treatment with a short-acting bronchodilator should be initiated.
Respocort should be discontinued immediately and alternative prophylactic therapy introduced. Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. 4). Commonly, when taking Respocort hoarseness and candidiasis of the mouth and throat may occur.
To reduce the risk of hoarseness and candida infection, patients are advised to rinse their mouth after using their inhaler. Based on the MedDRA system organ class and frequencies, adverse events are listed in the table below according to the following frequency estimate: very common (≥ 1/10); common (≥1/100 to <1/10); Uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
4 Special warnings and precautions for use). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
uk/yellowcard.

GBOfficial regulatory label· Warnings and precautions· revised October 31, 2025[1]

Patients should be properly instructed on the use of the inhaler to ensure that the drug reaches the target areas within the lungs. To be effective, Respocort must be used by patients on a regular basis, even when patients do not have asthma symptoms.
When symptoms are controlled, maintenance Respocort therapy should be reduced in a stepwise manner to the minimum effective dose. Inhaled steroid treatment should not be stopped abruptly. Patients with asthma are at risk of acute attacks and should have regular assessments of their asthma control including pulmonary function tests.
Respocort is not indicated for the immediate relief of asthma attacks. Patients therefore need to have relief medication (inhaled short-acting bronchodilator) available for such circumstances. Respocort is not indicated in the management of status asthmaticus.
Severe asthma exacerbations should be managed in the usual way. Subsequently, it may be necessary to increase the dose of Respocort up to the maximum daily dose. Systemic steroid treatment may be needed and/or an antibiotic, if there is an infection, together with β-agonist therapy, as needed.
Severe asthma requires regular medical assessment, including lung-function testing, as there is a risk of severe attacks and even death. Patients should be advised to seek medical attention as soon as possible for review of Respocort therapy if their peak flow falls, symptoms worsen or if their short-acting bronchodilator becomes less effective or increased inhalations than usual are required.
This may indicate deterioration of asthma control. If this occurs, patients should be assessed and the need for increased anti-inflammatory therapy considered (eg. higher doses of inhaled corticosteroid or a course of oral corticosteroid).
Patients who have received systemic steroids for long periods of time or at high doses, or both, need special care and subsequent management when being transferred to inhaled steroid therapy. Patients should have stable asthma before being given inhaled steroids in addition to the usual maintenance dose of systemic steroid.
Withdrawal of systemic steroids should be gradual, starting about seven days after the introduction of Respocort therapy. For daily oral doses of prednisolone of 10mg or less, dose reduction in 1mg steps, at intervals of not less than one week is recommended.
For patients on daily maintenance doses of oral prednisolone greater than 10mg, larger weekly reductions in the dose might be acceptable. The dose reduction scheme should be chosen to correlate with the magnitude of the maintenance systemic steroid dose.
Most patients can be successfully transferred to inhaled steroids with maintenance of good respiratory function, but special care is necessary for the first few months after the transfer, until the hypothalamic-pituitary-adrenal (HPA) system has sufficiently recovered to enable the patient to cope with stressful emergencies such as trauma, surgery or serious infections.

This is not medical advice. Consult a qualified healthcare professional.

Posology The recommended dose is two inhalations twice daily. The maximum dose is two inhalations twice daily. Special populations Elderly No dose adjustment is required in elderly patients (65 years of age and older). 73 m2) renal impairment.
2). 2). Paediatric population There is no relevant use of Trydonis in the paediatric population (under 18 years of age) for the indication of COPD. Method of administration For inhalation use. To ensure proper administration of the medicinal product, the patient should be shown how to use the inhaler correctly by a physician or other healthcare professional, who should also regularly check the adequacy of the patient’s inhalation technique (see “Instructions for use” below).
The patient should be advised to read the Package Leaflet carefully and follow the instructions for use as given in the leaflet. This medicinal product is provided with a dose counter or dose indicator on the back of the inhaler, which shows how many actuations are left.
For the 120 actuation pressurised container, each time the patient presses the container a puff of the solution is released and the counter counts down by one. For the 180 actuation pressurised container, each time the patient presses the pressurised container a puff of the solution is released and the indicator rotates by a small amount; the number of puffs remaining is displayed in intervals of 20.
The patient should be advised not to drop the inhaler as this may cause the counter to count down. Instructions for use Priming the inhaler Before using the inhaler for the first time, the patient should release one actuation into the air in order to ensure that the inhaler is working properly (priming).
Before priming the 120 or 180 actuation pressurised containers, the counter/indicator should read 121 or 180, respectively. After priming, the counter/indicator should read 120 or 180. Use of the inhaler The patient should stand or sit in an upright position when inhaling from the inhaler.
The steps below should be followed. IMPORTANT: steps 2 to 5 should not be performed too quickly: 1. The patient should remove the protective cap from the mouthpiece and check that the mouthpiece is clean and free from dust and dirt or any other foreign objects.
2. The patient should breathe out slowly and as deeply as comfortable, in order to empty the lungs. 3. The patient should hold the inhaler vertically with its body upwards and place the mouthpiece between the teeth without biting. The lips should then be placed around the mouthpiece, with the tongue flat under it.
4. At the same time, the patient should breathe in slowly and deeply through the mouth until the lungs are full of air (this should take approximately 4 – 5 seconds). Immediately after starting to breathe in, the patient should firmly press down on the top of the pressurised container to release one puff.
5. The patient should then hold the breath for as long as comfortably possible, then remove the inhaler from the mouth and breathe out slowly. The patient should not breathe out into the inhaler. 6. The patient should then check the dose counter or dose indicator to ensure it has moved accordingly.
4 To inhale the second puff, the patient should keep the inhaler in a vertical position for approximately 30 seconds and repeat steps 2 to 6. If mist appears after the inhalation, either from the inhaler or from the sides of the mouth, the procedure should be repeated from step 2.
After use, the patient should close the inhaler with the protective mouthpiece cap and check the dose counter or dose indicator. 4). When to get a new inhaler The patient should be advised to get a new inhaler when the dose counter or indicator shows the number 20.
He/she should stop using the inhaler when the counter or indicator shows 0 as any puffs left in the device may not be enough to release a full actuation. Additional instructions for specific groups of patients For patients with weak hands it may be easier to hold the inhaler with both hands.
Therefore, the index fingers should be placed on the top of the pressurised container and both thumbs on the base of the inhaler. Patients who find it difficult to synchronise aerosol actuation with inspiration of breath may use the AeroChamber Plus spacer device, properly cleaned as described in the relevant leaflet.
They should be advised by their doctor or pharmacist about the proper use and care of their inhaler and spacer and their technique checked to ensure optimum delivery of the inhaled active substance to the lungs. This may be obtained by the patients using the AeroChamber Plus by one continuous slow and deep breath through the spacer, without any delay between actuation and inhalation.
2). Cleaning For the regular cleaning of the inhaler, patients should remove weekly the cap from the mouthpiece and wipe the outside and inside of the mouthpiece with a dry cloth. They […]